Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 5/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250177 | 0.88 | NOTUM (0.47) | NOTUMARTRPV4CSF1RSLC6A9 | |
| SCHEMBL3532873 | 0.86 | NOTUM (0.48) | NOTUMARTRPV4CSF1RKDM4E | |
| SCHEMBL13175782 | 0.82 | AR (0.51) | ARKIF11TRPV4ALDH1A1MEN1 | |
| SCHEMBL8418329 | 0.79 | SLC6A9 (0.46) | ARCSF1RKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13736409 | 0.77 | SLC6A9 (0.44) | ARCSF1RKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL15117102 | 0.76 | SLC6A9 (0.57) | ARCSF1RALDH1A1MEN1GAA | |
| SCHEMBL16729408 | 0.76 | NOTUM (0.50) | NOTUMALDH1A1MEN1GAAKMT2A | |
| SCHEMBL30865737 | 0.75 | NOTUM (0.52) | NOTUMKDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL20830204 | 0.74 | DRD2 (0.49) | TRPV4ALDH1A1HSD11B1 | |
| SCHEMBL12684833 | 0.73 | NOTUM (0.51) | NOTUMARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1572632-B1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | XENTION LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | US | disclosed |
| EP-1572632-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052845-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135505-A1 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | OPRL1, PTGER1, LTB4R2 | NOTUM 2667/4885AR 297/4885KIF11 3658/4885 |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | NOTUM 2396/4885AR 253/4885KIF11 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.